Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

FGFR2-activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer cell models.

Stehbens SJ, Ju RJ, Adams MN, Perry SR, Haass NK, Bryant DM, Pollock PM.

J Cell Sci. 2018 Aug 10;131(15). pii: jcs213678. doi: 10.1242/jcs.213678.

PMID:
30002137
2.

Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance.

Ahmed F, Haass NK.

Front Oncol. 2018 May 24;8:173. doi: 10.3389/fonc.2018.00173. eCollection 2018. Review.

3.

Mathematical Models for Cell Migration with Real-Time Cell Cycle Dynamics.

Vittadello ST, McCue SW, Gunasingh G, Haass NK, Simpson MJ.

Biophys J. 2018 Mar 13;114(5):1241-1253. doi: 10.1016/j.bpj.2017.12.041.

PMID:
29539409
4.

Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo.

Oo ZY, Stevenson AJ, Proctor M, Daignault SM, Walpole S, Lanagan C, Chen J, Škalamera D, Spoerri L, Ainger SA, Sturm RA, Haass NK, Gabrielli B.

Clin Cancer Res. 2018 Jun 15;24(12):2901-2912. doi: 10.1158/1078-0432.CCR-17-2701. Epub 2018 Mar 13.

PMID:
29535131
5.

HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.

Gallagher SJ, Gunatilake D, Beaumont KA, Sharp DM, Tiffen JC, Heinemann A, Weninger W, Haass NK, Wilmott JS, Madore J, Ferguson PM, Rizos H, Hersey P.

Int J Cancer. 2018 May 1;142(9):1926-1937. doi: 10.1002/ijc.31199. Epub 2017 Dec 20.

PMID:
29210065
6.

Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers.

Hammerlindl H, Ravindran Menon D, Hammerlindl S, Emran AA, Torrano J, Sproesser K, Thakkar D, Xiao M, Atkinson VG, Gabrielli B, Haass NK, Herlyn M, Krepler C, Schaider H.

Clin Cancer Res. 2018 Mar 1;24(5):1090-1102. doi: 10.1158/1078-0432.CCR-16-2118. Epub 2017 Dec 1.

PMID:
29196297
7.

Real-Time Cell Cycle Imaging in a 3D Cell Culture Model of Melanoma.

Spoerri L, Beaumont KA, Anfosso A, Haass NK.

Methods Mol Biol. 2017;1612:401-416. doi: 10.1007/978-1-4939-7021-6_29.

PMID:
28634959
8.

Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure.

Smith MP, Rowling EJ, Miskolczi Z, Ferguson J, Spoerri L, Haass NK, Sloss O, McEntegart S, Arozarena I, von Kriegsheim A, Rodriguez J, Brunton H, Kmarashev J, Levesque MP, Dummer R, Frederick DT, Andrews MC, Cooper ZA, Flaherty KT, Wargo JA, Wellbrock C.

EMBO Mol Med. 2017 Aug;9(8):1011-1029. doi: 10.15252/emmm.201607156.

9.

Dendritic Mesoporous Silica Nanoparticles for pH-Stimuli-Responsive Drug Delivery of TNF-Alpha.

Kienzle A, Kurch S, Schlöder J, Berges C, Ose R, Schupp J, Tuettenberg A, Weiss H, Schultze J, Winzen S, Schinnerer M, Koynov K, Mezger M, Haass NK, Tremel W, Jonuleit H.

Adv Healthc Mater. 2017 Jul;6(13). doi: 10.1002/adhm.201700012. Epub 2017 May 29.

PMID:
28557249
10.

NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF.

Fane ME, Chhabra Y, Hollingsworth DEJ, Simmons JL, Spoerri L, Oh TG, Chauhan J, Chin T, Harris L, Harvey TJ, Muscat GEO, Goding CR, Sturm RA, Haass NK, Boyle GM, Piper M, Smith AG.

EBioMedicine. 2017 Feb;16:63-75. doi: 10.1016/j.ebiom.2017.01.013. Epub 2017 Jan 16.

11.

Cell cycle-tailored targeting of metastatic melanoma: Challenges and opportunities.

Haass NK, Gabrielli B.

Exp Dermatol. 2017 Jul;26(7):649-655. doi: 10.1111/exd.13303. Epub 2017 Apr 20.

PMID:
28109167
12.

JNK-ERK signalling in melanoma: rewired or entangled?

Haass NK.

Br J Dermatol. 2016 Dec;175(6):1139-1140. doi: 10.1111/bjd.14903. No abstract available.

PMID:
27996144
13.

Genome-wide gain-of-function screen for genes that induce epithelial-to-mesenchymal transition in breast cancer.

Škalamera D, Dahmer-Heath M, Stevenson AJ, Pinto C, Shah ET, Daignault SM, Said NA, Davis M, Haass NK, Williams ED, Hollier BG, Thompson EW, Gabrielli B, Gonda TJ.

Oncotarget. 2016 Sep 20;7(38):61000-61020. doi: 10.18632/oncotarget.11314.

14.

Multimodal tumor suppression by miR-302 cluster in melanoma and colon cancer.

Maadi H, Moshtaghian A, Taha MF, Mowla SJ, Kazeroonian A, Haass NK, Javeri A.

Int J Biochem Cell Biol. 2016 Dec;81(Pt A):121-132. doi: 10.1016/j.biocel.2016.11.004. Epub 2016 Nov 10.

PMID:
27840154
15.

microRNA-7-5p inhibits melanoma cell proliferation and metastasis by suppressing RelA/NF-κB.

Giles KM, Brown RA, Ganda C, Podgorny MJ, Candy PA, Wintle LC, Richardson KL, Kalinowski FC, Stuart LM, Epis MR, Haass NK, Herlyn M, Leedman PJ.

Oncotarget. 2016 May 31;7(22):31663-80. doi: 10.18632/oncotarget.9421.

16.

In vivo overexpression of Emi1 promotes chromosome instability and tumorigenesis.

Vaidyanathan S, Cato K, Tang L, Pavey S, Haass NK, Gabrielli BG, Duijf PH.

Oncogene. 2016 Oct 13;35(41):5446-5455. doi: 10.1038/onc.2016.94. Epub 2016 Apr 11.

PMID:
27065322
17.

Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells.

Beaumont KA, Hill DS, Daignault SM, Lui GYL, Sharp DM, Gabrielli B, Weninger W, Haass NK.

J Invest Dermatol. 2016 Jul;136(7):1479-1489. doi: 10.1016/j.jid.2016.02.805. Epub 2016 Mar 10.

18.

Imaging- and Flow Cytometry-based Analysis of Cell Position and the Cell Cycle in 3D Melanoma Spheroids.

Beaumont KA, Anfosso A, Ahmed F, Weninger W, Haass NK.

J Vis Exp. 2015 Dec 28;(106):e53486. doi: 10.3791/53486.

19.

Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS.

Ke YD, van Hummel A, Stevens CH, Gladbach A, Ippati S, Bi M, Lee WS, Krüger S, van der Hoven J, Volkerling A, Bongers A, Halliday G, Haass NK, Kiernan M, Delerue F, Ittner LM.

Acta Neuropathol. 2015 Nov;130(5):661-78. doi: 10.1007/s00401-015-1486-0. Epub 2015 Oct 5.

PMID:
26437864
20.

Dynamic tumor heterogeneity in melanoma therapy: how do we address this in a novel model system?

Haass NK.

Melanoma Manag. 2015 May;2(2):93-95. doi: 10.2217/mmt.15.1. Epub 2015 May 18. No abstract available.

21.

Switching the sphingolipid rheostat in the treatment of diabetes and cancer comorbidity from a problem to an advantage.

Haass NK, Nassif N, McGowan EM.

Biomed Res Int. 2015;2015:165105. doi: 10.1155/2015/165105. Epub 2015 Mar 19. Review.

22.

Expression of Bcl-xL and Mcl-1 in the nonmelanoma skin cancers of renal transplant recipients.

Burke MT, Morais C, Oliver KA, Lambie DL, Gobe GC, Carroll RP, Staatz CE, Sinnya S, Soyer HP, Winterford C, Haass NK, Campbell SB, Isbel NM.

Am J Clin Pathol. 2015 Apr;143(4):514-26. doi: 10.1309/AJCPQNB5WA3PLQBK.

PMID:
25780003
23.

Friends or foes: IL-10 and TGF-β in melanoma.

Tikoo S, Haass NK.

Exp Dermatol. 2015 Apr;24(4):254-5. doi: 10.1111/exd.12661. No abstract available.

PMID:
25661188
24.

A stress-induced early innate response causes multidrug tolerance in melanoma.

Menon DR, Das S, Krepler C, Vultur A, Rinner B, Schauer S, Kashofer K, Wagner K, Zhang G, Rad EB, Haass NK, Soyer HP, Gabrielli B, Somasundaram R, Hoefler G, Herlyn M, Schaider H.

Oncogene. 2015 Aug 20;34(34):4545. doi: 10.1038/onc.2014.432. Epub 2015 Jan 26.

PMID:
25619837
25.

A stress-induced early innate response causes multidrug tolerance in melanoma.

Ravindran Menon D, Das S, Krepler C, Vultur A, Rinner B, Schauer S, Kashofer K, Wagner K, Zhang G, Bonyadi Rad E, Haass NK, Soyer HP, Gabrielli B, Somasundaram R, Hoefler G, Herlyn M, Schaider H.

Oncogene. 2015 Aug 20;34(34):4448-59. doi: 10.1038/onc.2014.372. Epub 2014 Nov 24. Erratum in: Oncogene. 2015 Aug 20;34(34):4545.

26.

Induction of endoplasmic reticulum stress as a strategy for melanoma therapy: is there a future?

Hill DS, Lovat PE, Haass NK.

Melanoma Manag. 2014 Nov;1(2):127-137. doi: 10.2217/mmt.14.16. Epub 2014 Dec 4. Review.

27.

Detection of primary melanoma in individuals at extreme high risk: a prospective 5-year follow-up study.

Moloney FJ, Guitera P, Coates E, Haass NK, Ho K, Khoury R, O'Connell RL, Raudonikis L, Schmid H, Mann GJ, Menzies SW.

JAMA Dermatol. 2014 Aug;150(8):819-27. doi: 10.1001/jamadermatol.2014.514.

PMID:
24964862
28.

Real-time cell cycle imaging during melanoma growth, invasion, and drug response.

Haass NK, Beaumont KA, Hill DS, Anfosso A, Mrass P, Munoz MA, Kinjyo I, Weninger W.

Pigment Cell Melanoma Res. 2014 Sep;27(5):764-76. doi: 10.1111/pcmr.12274. Epub 2014 Jun 27.

PMID:
24902993
29.

Melanoma never says die.

Haass NK, Schumacher U.

Exp Dermatol. 2014 Jul;23(7):471-2. doi: 10.1111/exd.12400.

PMID:
24684560
30.

Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy.

Mohana-Kumaran N, Hill DS, Allen JD, Haass NK.

Pigment Cell Melanoma Res. 2014 Jul;27(4):525-39. doi: 10.1111/pcmr.12242. Epub 2014 Apr 9.

PMID:
24655414
31.

Targeting glutamine transport to suppress melanoma cell growth.

Wang Q, Beaumont KA, Otte NJ, Font J, Bailey CG, van Geldermalsen M, Sharp DM, Tiffen JC, Ryan RM, Jormakka M, Haass NK, Rasko JE, Holst J.

Int J Cancer. 2014 Sep 1;135(5):1060-71. doi: 10.1002/ijc.28749. Epub 2014 Feb 17.

32.

A novel class of anticancer compounds targets the actin cytoskeleton in tumor cells.

Stehn JR, Haass NK, Bonello T, Desouza M, Kottyan G, Treutlein H, Zeng J, Nascimento PR, Sequeira VB, Butler TL, Allanson M, Fath T, Hill TA, McCluskey A, Schevzov G, Palmer SJ, Hardeman EC, Winlaw D, Reeve VE, Dixon I, Weninger W, Cripe TP, Gunning PW.

Cancer Res. 2013 Aug 15;73(16):5169-82. doi: 10.1158/0008-5472.CAN-12-4501. Erratum in: Cancer Res. 2013 Oct 1;73(19):6094.

33.

Melanoma's connections to the tumour microenvironment.

Brandner JM, Haass NK.

Pathology. 2013 Aug;45(5):443-52. doi: 10.1097/PAT.0b013e328363b3bd. Review.

PMID:
23851614
34.

DNA repair and cell cycle checkpoint defects as drivers and therapeutic targets in melanoma.

Pavey S, Spoerri L, Haass NK, Gabrielli B.

Pigment Cell Melanoma Res. 2013 Nov;26(6):805-16. doi: 10.1111/pcmr.12136. Epub 2013 Aug 5. Review.

PMID:
23837768
35.

A quantitative approach to histopathological dissection of elastin-related disorders using multiphoton microscopy.

Tong PL, Qin J, Cooper CL, Lowe PM, Murrell DF, Kossard S, Ng LG, Roediger B, Weninger W, Haass NK.

Br J Dermatol. 2013 Oct;169(4):869-79. doi: 10.1111/bjd.12430.

PMID:
23662922
36.

Modeling Melanoma In Vitro and In Vivo.

Beaumont KA, Mohana-Kumaran N, Haass NK.

Healthcare (Basel). 2013 Dec 23;2(1):27-46. doi: 10.3390/healthcare2010027. Review.

37.

The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance.

Wroblewski D, Mijatov B, Mohana-Kumaran N, Lai F, Gallagher SJ, Haass NK, Zhang XD, Hersey P.

Carcinogenesis. 2013 Feb;34(2):237-47. doi: 10.1093/carcin/bgs330. Epub 2012 Oct 20.

PMID:
23087082
38.

Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.

Lucas KM, Mohana-Kumaran N, Lau D, Zhang XD, Hersey P, Huang DC, Weninger W, Haass NK, Allen JD.

Clin Cancer Res. 2012 Feb 1;18(3):783-95. doi: 10.1158/1078-0432.CCR-11-1166. Epub 2011 Dec 15.

39.

Meeting report from the 2011 International Melanoma Congress, Tampa, Florida.

Smalley KS, Aplin AE, Flaherty KT, Hoeller C, Bosserhoff AK, Haass NK, Bosenberg M, Ribas A, Barnhill R, Kudchadkar R, Messina JL.

Pigment Cell Melanoma Res. 2012 Jan;25(1):E1-11. doi: 10.1111/j.1755-148X.2011.00943.x. Epub 2011 Dec 9. No abstract available.

PMID:
22117673
40.

Evaluation of cell cycle arrest in estrogen responsive MCF-7 breast cancer cells: pitfalls of the MTS assay.

McGowan EM, Alling N, Jackson EA, Yagoub D, Haass NK, Allen JD, Martinello-Wilks R.

PLoS One. 2011;6(6):e20623. doi: 10.1371/journal.pone.0020623. Epub 2011 Jun 3.

41.

Meeting report from the 7th International Melanoma Congress, Sydney, November, 2010.

Hersey P, Smalley KS, Weeraratna A, Bosenberg M, Zhang XD, Haass NK, Paton E, Mann G, Scolyer RA, Tüting T.

Pigment Cell Melanoma Res. 2011 Feb;24(1):e1-15. doi: 10.1111/j.1755-148X.2010.00811.x. Epub 2010 Dec 22. Erratum in: Pigment Cell Melanoma Res. 2011 Oct;24(5):989. Tüting, T [added].

PMID:
21232023
42.

Multiple desmoplastic melanomas in Birt-Hogg-Dubé syndrome and a proposed signaling link between folliculin, the mTOR pathway, and melanoma susceptibility.

Cocciolone RA, Crotty KA, Andrews L, Haass NK, Moloney FJ.

Arch Dermatol. 2010 Nov;146(11):1316-8. doi: 10.1001/archdermatol.2010.333. No abstract available.

PMID:
21079084
43.

PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas.

Lee JT, Li L, Brafford PA, van den Eijnden M, Halloran MB, Sproesser K, Haass NK, Smalley KS, Tsai J, Bollag G, Herlyn M.

Pigment Cell Melanoma Res. 2010 Dec;23(6):820-7. doi: 10.1111/j.1755-148X.2010.00763.x.

44.

Genetics of basal cell carcinoma.

de Zwaan SE, Haass NK.

Australas J Dermatol. 2010 May;51(2):81-92; quiz 93-4. doi: 10.1111/j.1440-0960.2009.00579.x. Review.

PMID:
20546211
45.

Melanoma progression exhibits a significant impact on connexin expression patterns in the epidermal tumor microenvironment.

Haass NK, Ripperger D, Wladykowski E, Dawson P, Gimotty PA, Blome C, Fischer F, Schmage P, Moll I, Brandner JM.

Histochem Cell Biol. 2010 Jan;133(1):113-24. doi: 10.1007/s00418-009-0654-5. Epub 2009 Oct 21.

PMID:
19844737
46.

Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy.

Haass NK, Smalley KS.

Mol Diagn Ther. 2009;13(5):283-96. doi: 10.2165/11317270-000000000-00000. Review.

PMID:
19791833
47.

Melanocytes: from morphology to application.

Santiago-Walker A, Li L, Haass NK, Herlyn M.

Skin Pharmacol Physiol. 2009;22(2):114-21. doi: 10.1159/000178870. Epub 2009 Feb 4.

PMID:
19188759
48.

From Xiphophorus to melanoma--a tribute to Steven Kazianis (1966-2008).

Haass NK.

Zebrafish. 2008 Summer;5(2):91-2. No abstract available.

PMID:
18554171
49.

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.

Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K, Li L, Smalley KS, Fong D, Zhu YL, Marimuthu A, Nguyen H, Lam B, Liu J, Cheung I, Rice J, Suzuki Y, Luu C, Settachatgul C, Shellooe R, Cantwell J, Kim SH, Schlessinger J, Zhang KY, West BL, Powell B, Habets G, Zhang C, Ibrahim PN, Hirth P, Artis DR, Herlyn M, Bollag G.

Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3041-6. doi: 10.1073/pnas.0711741105. Epub 2008 Feb 19.

50.

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.

Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, Herlyn M, Smalley KS.

Clin Cancer Res. 2008 Jan 1;14(1):230-9. doi: 10.1158/1078-0432.CCR-07-1440.

Supplemental Content

Loading ...
Support Center